Premium
Clinical Use of Interferon‐γ
Author(s) -
Miller Catriona H.T.,
Maher Stephen G.,
Young Howard A.
Publication year - 2009
Publication title -
annals of the new york academy of sciences
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.712
H-Index - 248
eISSN - 1749-6632
pISSN - 0077-8923
DOI - 10.1111/j.1749-6632.2009.05069.x
Subject(s) - tolerability , cytokine , clinical trial , immune system , immunology , medicine , interferon gamma , interferon , pharmacology , adverse effect
Interferon gamma (IFN‐γ), a pleotropic cytokine, has been shown to be important to the function of virtually all immune cells and both innate and adaptive immune responses. In 1986, early clinical trials of this cytokine began to evaluate its therapeutic potential. The initial studies focused on the tolerability and pharmacology of IFN‐γ and systematically determined its antitumor and anti‐infection activities. In the 20‐plus years since those first trials, IFN‐γ has been used in a wide variety of clinical indications, which are reviewed in this article.